Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAAJP1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

4/13/05 10/789019a
structure search CAPLUS - 7 hits
BEILSTEIN - 0 hits
CAOLD - 0 hits
GMELIN - 0 hits
CASREACT - 8 hits

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced



NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

$G_1 = C, O$

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:56:24 ON 13 APR 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:56:39 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2005 HIGHEST RN 848391-87-7
DICTIONARY FILE UPDATES: 12 APR 2005 HIGHEST RN 848391-87-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789019\10789019a.str



chain nodes :
7 8 9 11 12 16 17 19 27
ring nodes :
1 2 3 4 5 6 22 23 24 25 26
chain bonds :
3-11 7-8 8-9 11-12 12-16 16-17 17-19 19-24 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 22-23 22-26 23-24 24-25 25-26
exact/norm bonds :
7-8 8-9 11-12 12-16 16-17 17-19 22-23 22-26 23-24 24-25 25-26 26-27
exact bonds :
3-11 19-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 16:Atom 17:CLASS 19:CLASS 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 18:57:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3613 TO ITERATE

27.7% PROCESSED 1000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 68656 TO 75864
PROJECTED ANSWERS: 19 TO 413

L2 3 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 18:57:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72008 TO ITERATE

100.0% PROCESSED 72008 ITERATIONS 115 ANSWERS
SEARCH TIME: 00.00.02

L3 115 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 18:57:11 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Apr 2005 VOL 142 ISS 16
FILE LAST UPDATED: 12 Apr 2005 (20050412/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L4 7 L3

=> d L4 1-7 ibib abs hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:120864 CAPLUS
DOCUMENT NUMBER: 142:219048
TITLE: Preparation of diphenyl ether derivatives as PPARδ agonists
INVENTOR(S): Kusuda, Shinya; Nakayama, Yoshisuke; Ima, Masaki; Tajima, Hisao; Kato, Sachiko
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012221	A1	20050210	WO 2004-JP11424	20040803

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2003-286199 A 20030804
GI



I



II

AB The title compds. I [wherein rings A, B, and D = independently (un)substituted (hetero)cycle; W = a spacer; X = a spacer; Y = a bond or a spacer; Z = a acid group], or salts, solvates, or prodrugs thereof are prepared as peroxisome proliferator-activated receptors (PPAR) agonists. For example, the compound II was prepared in a multi-step synthesis. II increased HDL level and lowered LDL level in rat. I are useful as a preventive and/or therapeutic agent for diseases caused by sugar/lipid abnormal metabolism (diabetes, hyperlipemia, arteriosclerosis, cardiovascular diseases, obesity, metabolic syndrome, etc.), hypertension, circulatory diseases, inflammatory skin diseases, etc. (no data). Formulations containing I as an active ingredient were also described.

IT **840542-59-8P 840542-63-4P 840542-66-7P 840542-94-1P 840543-25-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of di-Ph ether derivs. as PPARδ agonists)

RN 840542-59-8 CAPLUS

CN Benzoic acid, 2-[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-63-4 CAPLUS

CN Benzoic acid, 2-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



ours is non-aromatic

RN 840542-66-7 CAPLUS
CN Benzoic acid, 3-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-94-1 CAPLUS
CN Benzoic acid, 3-[2-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840543-25-1 CAPLUS
CN Benzoic acid, 3-[2-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:740279 CAPLUS
DOCUMENT NUMBER: 141:260285
TITLE: Method for producing the enantiomeric forms of cis-1,3-cyclohexanediol derivatives using an enzymic resolution
INVENTOR(S): Holla, Wolfgang; Keil, Stefanie
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004076390	A1	20040910	WO 2004-EP1580		20040219
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
DE 10308350	A1	20040916	DE 2003-10308350		20030227
US 2004209931	A1	20041021	US 2004-789053		20040227
PRIORITY APPLN. INFO.:			DE 2003-10308350	A	20030227
			US 2003-487416P	P	20030715

OTHER SOURCE(S): MARPAT 141:260285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method for producing chiral, non-racemic, disubstituted cis-1,3-cyclohexanediols I [R1 = R'; A = Ph, 5- to 10-membered heteroarom. (containing N, O, S), C8-14-aromatic, C3-8-cycloalkyl; R3 = H, F, Cl, Br, OH, NO2, CF3, OCF3, C1-6-alkyl, C3-8-cycloalkyl, Ph; R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, OCHF2, OCF2CF3, OCF2CHF2, SCF3, OPh, C1-6-alkyl, O-(C1-6-alkyl), O-(C1-6-alkyl)-O-(C1-3-alkyl); n = 1 - 3; R2 = C1-8-alkyl, optionally, one or more CH2 may be replaced with an O, CO, S, SO, SO2 and substituted with 1 - 3 substituents {F, Cl, Br, CF3, Cn, NO2, NHAc, NHBoc, NHCOCMe3, OH, OCF3, O-(C1-6-alkyl), CO2H, CO2CH2Ph, CO2-(C1-6-alkyl), tetrazole, indole, (un)substituted thiazolidine-2,4-dione, C6-10-aryl }, or, protecting group (PG) {e.g., CH2OCH2Ph, CH2Ph, CH2C6H4OMe-p, SiMe2CMe3}] using an enzymic resolution of racemates. The preparation of chiral cis-I is characterized by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with R2X1 [X1 = Cl, Br, I, OSO2Me (OMs), OSO2C6H4Me-p (OTs), OSO2CF3 (OTf)] in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resolution of (±)-cis-I (R1 = H) with an acyl donor, R6Cl or (R6)2O [R6 = C(:O)-(C1-16-alkyl), C(:O)-(C2-16-alkenyl), C(:O)-(C3-16-alkynyl), C(:O)-(C3-16-cycloalkyl), optionally one or more CH2 may be replaced with O substituted with 1 - 3 substituents {F, Cl, Br, CF3, CN, NO2, OH, OMe, OEt, Ph, CO2-(C1-4-alkyl), CO2-(C2-4-alkenyl)}], in an organic solvent containing an enzyme; (c) chemical hydrolysis of chiral cis-I (R1 = R6); (d) alkylation of chiral cis-I (R1 = H) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent. Alternatively chiral cis-I is prepared by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with PG-X1 [X1 = Cl, Br, I, OMs, OTs, OTf] in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resolution of (±)-cis-I (R1 = H, R2 = PG) with an acyl donor, R6Cl or (R6)2O, in an organic solvent containing an enzyme; (c) chemical hydrolysis of chiral cis-I (R1 = R6, R2 = PG); (d) alkylation of chiral cis-I (R1 = H; R2 = PG) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent (e) deprotecting chiral cis-I (R2 = PG); (f) alkylation of chiral cis-I (R2 = H) with R2X1 in the presence of a base and a suitable solvent. Thus, cyclohexanediol derivative

II was prepared from (±)-cis-1,3-cyclohexanediol via alkylation with Me 2-(bromomethyl)-6-methylbenzoate in NMP containing KOCMe3, enzymic resolution with vinyl acetate in CH2Cl2 containing Novozym 435, alkylation of the resulting chiral (benzyloxy)cyclohexanol III with (iodomethyl)oxazole IV, and saponification with NaOH in EtOH.

IT **501362-77-2P 710281-33-7P 710281-37-1P 710281-48-4P 755030-33-2P 755030-34-3P**
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution)

RN 501362-77-2 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



not w/in range of R1

RN 710281-33-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



no

RN 710281-37-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



no

RN 710281-48-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 755030-23-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755030-27-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:740108 CAPLUS
DOCUMENT NUMBER: 141:260734
TITLE: Preparation of diarylcycloalkyl oxazole derivatives and their use in the treatment of, e.g., fatty acid metabolism
INVENTOR(S): Goerlitzer, Jochen; Glombik, Heiner; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075815	A2	20040910	WO 2004-EP1584	20040219
WO 2004075815	A3	20041229		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308353	A1	20041202	DE 2003-10308353	20030227
US 2004204462	A1	20041014	US 2004-789019	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308353 A	20030227
			US 2003-494911P P	20030813

OTHER SOURCE(S): MARPAT 141:260734

GI



I



II

AB Title compds. I [A = cycloalkanediyl, cycloalkenediyl, etc.; B = Ph, heterocyclic, etc.; R1 = SCF3, OCF2-CHF2, phenoxy, etc.; R2 = H, CF3; R3 = H, alkyl; R4 = Ph, H, F, Cl, Br, etc.; R5 = H, F, Cl, Br, OH, etc.; X, Y = alkanediyl, etc.] are prepared For instance, 2-Methyl-6-[(((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid (II) is prepared in 7 steps using naphthalene-2-carboxaldehyde, diacetylmonooxime, 1,3-cyclohexanediol and 2-bromomethyl-6-methylbenzoic acid Me ester. II has an EC50 = 0.2 nM for the PPARα receptor. I are useful for treating disorders of the fatty acid metabolism and glucose utilization in addition to disorders of insulin resistance.

IT **755016-26-3P**, 2-[(((1R,3S)-3-((2-(3-Fluoro-5-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid methyl ester



RN 755016-32-1 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-cyclohexyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **755016-11-6P**, 2-Methyl-6-[(((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)
RN 755016-11-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:513338 CAPLUS
DOCUMENT NUMBER: 141:71532
TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators
INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 231,432.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122069	A1	20040624	US 2003-631867	20030801
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210

PRIORITY APPLN. INFO.: DE 2001-10142734 A 20010831
DE 2002-10223273 A 20020524
US 2002-231432 A2 20020830

OTHER SOURCE(S): MARPAT 141:71532
GI



I



II

AB Title oxazoles I [Z = cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, etc.; R3 = H, Me; X, Y = alkyl (chains may contain 1 or more oxygens)] are prepared Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(Iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPARα].

IT **710281-44-0P**, 2-[[[(1R,3S)-3-[[2-(3-Bromophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-44-0 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **710281-30-4P**, Methyl 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoate
710281-32-6P, 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-33-7P, 2-[[[(1R,3S)-3-[[2-(3-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-34-8P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-35-9P, 2-[[[(1R,3S)-3-[[2-(3-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-36-0P, 2-[[[(1R,3S)-3-[[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-37-1P, 2-[[[(1R,3S)-3-[[2-(3-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-38-2P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-39-3P, 2-[[[(1R,3S)-3-[[2-(2,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-40-6P, 2-[[[(1R,3S)-3-[[2-(2-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-41-7P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-42-8P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-43-9P, 2-[[[(1R,3S)-3-[[2-(3-Cyanophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-45-1P, 2-Methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-46-2P**, 2-Methyl-6-[[[(1S,3R)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-48-4P**, 2-Methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-49-5P**, 2-Methyl-6-[[[(1S,3R)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-50-8P**, 2-[[[(1R,3S)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-51-9P, 2-[[[(1S,3R)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-56-4P, 2-Methyl-6-[[[(1S,4R)-4-((5-methyl-2-phenyloxazol-4-yl)methoxy)cyclopent-2-enyl]oxy]methyl]benzoic Acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-30-4 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 710281-32-6 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-33-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-34-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-35-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-36-0 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-37-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-38-2 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-39-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-40-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-41-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-42-8 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-43-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-45-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-46-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-48-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-49-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-50-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-51-9 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-56-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **710281-55-3P**, Methyl 2-methyl-6-[[[(1S,4R)-4-((5-methyl-2-phenyloxazol-4-yl)methoxy)cyclopent-2-enyl]oxy]methyl]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)
RN 710281-55-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-02-3P 501362-03-4P 501362-06-7P**
501362-09-0P 501362-12-5P 501362-15-8P
501362-16-9P 501362-21-6P 501362-27-2P
501362-28-3P 501362-29-4P 501362-30-7P
501362-31-8P 501362-38-5P 501362-39-6P
501362-43-2P 501362-45-4P 501362-46-5P
501362-47-6P 501362-48-7P 501362-49-8P
501362-50-1P 501362-52-3P 501362-53-4P
501362-54-5P 501362-55-6P 501362-58-9P
501362-59-0P 501362-60-3P 501362-61-4P
501362-62-5P 501362-65-8P 501362-67-0P
501362-70-5P 501362-73-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-02-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-03-4 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-06-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-09-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-12-5 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-15-8 CAPLUS
CN Benzoic acid, 5-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-16-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-21-6 CAPLUS
CN Benzoic acid, 2-[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-27-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,2R)-2-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-28-3 CAPLUS
CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-29-4 CAPLUS
CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]-2-cyclopenten-1-yl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-30-7 CAPLUS
CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-31-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-38-5 CAPLUS
CN Benzoic acid, 2-[2-[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-39-6 CAPLUS
CN Benzoic acid, 2-[2-[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-43-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-45-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-46-5 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-47-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-48-7 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-49-8 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-50-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-52-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-53-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, cyanolysis and PPAR activating activity of; preparation of oxazole
diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-44-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT **501362-64-7P 501362-78-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-64-7 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 501362-78-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:202470 CAPLUS
DOCUMENT NUMBER: 138:238169
TITLE: Method for producing diaryl cycloalkyl derivatives of

oxazole and the use thereof as PPAR activators

INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwing; Schwink, Lothar; Wendler, Wolfgang

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
EE 200400059	A	20040415	EE 2004-59	20020817
EP 1425014	A1	20040609	EP 2002-797589	20020817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012158	A	20040713	BR 2002-12158	20020817
ZA 2004001073	A	20040826	ZA 2004-1073	20040210

PRIORITY APPLN. INFO.:

DE 2001-10142734	A	20010831
DE 2002-10223273	A	20020524
WO 2002-EP9221	W	20020817

OTHER SOURCE(S): MARPAT 138:238169

GI



I



II

AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, C1-6-alkyl, O-(C1-6-alkyl); R3 = H, C1-6-alkyl; X, Y = C1-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(Iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPARα].

IT **501362-02-3P 501362-03-4P 501362-06-7P**
501362-09-0P 501362-12-5P 501362-15-8P
501362-16-9P 501362-21-6P 501362-27-2P
501362-28-3P 501362-29-4P 501362-30-7P
501362-31-8P 501362-38-5P 501362-39-6P
501362-43-2P 501362-45-4P 501362-46-5P
501362-47-6P 501362-48-7P 501362-49-8P
501362-50-1P 501362-52-3P 501362-53-4P
501362-54-5P 501362-55-6P 501362-58-9P
501362-59-0P 501362-60-3P 501362-61-4P
501362-62-5P 501362-65-8P 501362-67-0P
501362-70-5P 501362-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-02-3 CAPLUS

CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



not w/in scope of R1

RN 501362-03-4 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-06-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-09-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-12-5 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-64-7P 501362-78-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-64-7 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 501362-78-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:772613 CAPLUS
DOCUMENT NUMBER: 133:335164
TITLE: Tri-aryl acid derivatives as PPAR receptor ligands
INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.; Labaudiniere, Richard F.; Zhang, Litao; Caulfield, Thomas J.; Minnich, Anne; Bobko, Mark; Morris, Robert; Groneberg, Robert D.; Mcgarry, Daniel G.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064876	A1	20001102	WO 2000-US11490	20000428
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371308	AA	20001102	CA 2000-2371308	20000428
EP 1177176	A1	20020206	EP 2000-930210	20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010126	A	20020226	BR 2000-10126	20000428
EE 200100558	A	20021216	EE 2001-558	20000428
NZ 515087	A	20031128	NZ 2000-515087	20000428
ZA 2001008800	A	20030210	ZA 2001-8800	20011024
NO 2001005226	A	20011205	NO 2001-5226	20011025
HR 2001000793	A1	20030228	HR 2001-793	20011026

PRIORITY APPLN. INFO.: US 1999-131454P P 19990428
WO 2000-US11490 W 20000428

OTHER SOURCE(S): MARPAT 133:335164
GI



I



II

AB This invention is directed to triaryl acid derivs. I and their salts, N-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkemyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, NHCONH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonylaminocarbonyl, sulfonylamino, carbamoyl, tetrazolyl, etc.; R1, R3, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-5; p = 0-4; q = 0-6; with numerous

provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid underwent a sequence of: (1) Me esterification, (2) benzylic monobromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alkaline hydrolysis with NaOH in aqueous EtOH, to give title compound II.

IT **303218-33-9P 303218-47-5P 303219-55-8P**
303219-57-0P 303219-59-2P 303219-78-5P
303220-12-4P 303220-98-6P 303221-34-3P
303221-36-5P 303221-38-7P 303221-40-1P
303221-44-5P 303221-87-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tri-aryl acid derivs. as PPAR receptor ligands)

RN 303218-33-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303218-47-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-55-8 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-57-0 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-59-2 CAPLUS
CN Benzoic acid, 2-[[3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-78-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[[2-(5-methyl-2-thienyl)-4-oxazolyl]methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-12-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-98-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-34-3 CAPLUS

CN Benzoic acid, 2-methyl-6-[[3-[[2-(5-methyl-2-thienyl)-4-oxazolyl]methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-36-5 CAPLUS
CN Benzoic acid, 2-[[3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



different ours is non-aromatic

RN 303221-38-7 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-40-1 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-44-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-87-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:54537 CAPLUS
DOCUMENT NUMBER: 120:54537
TITLE: Preparation of 4-(phenoxyalkyl)-2-oxazolines as acaricides and insecticides
INVENTOR(S): Hirose, Taro; Kisida, Hirosi; Saito, Shigeru; Fujimoto, Hiroaki
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 553623	A1	19930804	EP 1993-100223	19930108
EP 553623	B1	20010404		
R: CH, DE, ES, FR, GB, IT, LI				
AU 9230491	A1	19930729	AU 1992-30491	19921231
AU 658955	B2	19950504		
ES 2155442	T3	20010516	ES 1993-100223	19930108
BR 9300299	A	19930803	BR 1993-299	19930127
JP 05271206	A2	19931019	JP 1993-11698	19930127
JP 3239508	B2	20011217		
US 5411979	A	19950502	US 1993-10015	19930127
PRIORITY APPLN. INFO.:			JP 1992-12967 A	19920128

OTHER SOURCE(S): MARPAT 120:54537
GI



I

AB Title compds. [I; H, halo, (halo)alkyl, alkoxy, etc.; R2 = H, halo, alkyl, alkoxy, alkylthio; R3 = H, Me; R4 = (substituted) Ph; p = 1-4] were prepared Thus, 4-(Me3C)C6H4OH was condensed with BrCH2CH(OMe)2 and the product converted in 4 steps to 4-(Me3C)C6H4OCH2CH(NH2)CH2OH which was cyclocondensed with 2,6-F2C6H2COCl to give I (R1 = CMe3, R2 = R3 = H, R4 = C6H3F2-2,6) which gave ≥90% control of Culex pipiens pallens larvae in H2O containing 3.5 ppm.

IT **151856-99-4P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as acaricide and insecticide)

RN 151856-99-4 CAPLUS

CN Benzoic acid, 3-chloro-4-[4-[[2-(2,6-difluorophenyl)-4,5-dihydro-4-oxazolyl]methoxy]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



=> fil beilstein

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	39.08	200.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

FILE 'BEILSTEIN' ENTERED AT 19:03:22 ON 13 APR 2005

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON February 14, 2005

FILE COVERS 1771 TO 2004.
*** FILE CONTAINS 9,133,317 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search

for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************
```

NEW

* **PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.**
* **NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

```
=> d his

     (FILE 'HOME' ENTERED AT 18:56:24 ON 13 APR 2005)

     FILE 'REGISTRY' ENTERED AT 18:56:39 ON 13 APR 2005
L1             STRUCTURE UPLOADED
L2           3 S L1
L3         115 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 18:57:11 ON 13 APR 2005
L4           7 S L3

     FILE 'BEILSTEIN' ENTERED AT 19:03:22 ON 13 APR 2005

=> s L3
L5           0 L3

=> fil caold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                2.36     202.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -5.11

FILE 'CAOLD' ENTERED AT 19:03:48 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.
```

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s L3
L6 0 L3

=> fil gmelin
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.43 203.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -5.11

FILE 'GMELIN' ENTERED AT 19:03:59 ON 13 APR 2005
COPYRIGHT (C) 2005 MDL Information Systems GmbH

FILE LAST UPDATED: 03 MAY 97 - 21 MAY 97 <970503/UP -970521/UP>

>>> CAS REGISTRY NUMBERS FOR 171,499 SUBSTANCES AVAILABLE <<<
>>> FILE CONTAINS 1,070,350 SUBSTANCES <<<
>>> PLEASE NOTE THAT AFTER A SEARCH IN SSTA FIELDS DIS QRD OR DIS HIT CAN BE VERY LENGTHY. <<<

```
**********************************************************************
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR PREDEFINED   *
* FORMATS ARE BASED ON THE SUM OF ALL FIELDS POSSIBLE. THEREFORE;    *
* THESE ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                  *
* FOR PRICE INFORMATION SEE HELP COST.                               *
**********************************************************************
```

=> s L3
L7 0 L3

=> fil casreact
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 3.04 206.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -5.11

FILE 'CASREACT' ENTERED AT 19:04:11 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTENT:1840 - 10 Apr 2005 VOL 142 ISS 15

```
************************************************************
*                                                          *
*     CASREACT now has more than  8 million reactions      *
*                                                          *
************************************************************
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L8 0 L3

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.68	234.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.11

FILE 'CAPLUS' ENTERED AT 19:04:35 ON 13 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Apr 2005 VOL 142 ISS 16
FILE LAST UPDATED: 12 Apr 2005 (20050412/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	234.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.11

STN INTERNATIONAL LOGOFF AT 19:04:41 ON 13 APR 2005